Skip to main content
Top
Published in: Clinical Drug Investigation 3/2016

01-03-2016 | Original Research Article

Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study

Authors: Cécile Charles, Darius Razavi, Catherine Bungener, Christine Mateus, Emilie Lanoy, Michèle Verschoore, Sarah Dauchy, Caroline Robert

Published in: Clinical Drug Investigation | Issue 3/2016

Login to get access

Abstract

Background and objective

Body-image issues associated with dermatological side effects induced by anticancer-targeted therapies have not been specifically explored until now despite growing literature about their impact on quality of life. Prospective and longitudinal investigations were needed. The aim of our study was to describe body-image changes occurring with cutaneous toxicities and their psychosocial impact on patients.

Patients and methods

Thirty-three patients were evaluated four times during the first 3 months of targeted therapy in terms of body satisfaction, physical attitudes and depression with validated and ad hoc questionnaires. The NCI-CTCAE V4.0 was used to grade adverse dermatological events. Descriptive and inferential analyses were conducted with SPSS 14.0 software.

Results

Ninety-four per cent of the patients developed skin toxicities. Body satisfaction remained stable and slightly better than average over this period. About one-third of the patients reported body-image issues at baseline. Body satisfaction and depression levels at baseline appeared to be significantly associated with body-image issues after 3 months of therapy.

Conclusion

In the framework of regular dermatological monitoring, skin toxicities did not appear to be associated with body-image issues. Body satisfaction and depressive symptoms at the beginning of targeted therapy emerged as critical factors that practitioners should consider in order to prevent deterioration of body image that could impact on quality of life and compromise compliance.
Literature
1.
go back to reference Deslandres M, Sibaud V, Chevreau C, et al. Effets secondaires cutanés des nouvelles molécules anticancéreuses: focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l’EGF. Ann Dermatol Venereol. 2008;135(Suppl 1):16–24.CrossRef Deslandres M, Sibaud V, Chevreau C, et al. Effets secondaires cutanés des nouvelles molécules anticancéreuses: focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l’EGF. Ann Dermatol Venereol. 2008;135(Suppl 1):16–24.CrossRef
2.
go back to reference Mateus C, Robert C. Effets cutanés des nouvelles molécules utilisés en cancérologie. Rev Med Interne. 2009;30:401–10.CrossRefPubMed Mateus C, Robert C. Effets cutanés des nouvelles molécules utilisés en cancérologie. Rev Med Interne. 2009;30:401–10.CrossRefPubMed
3.
go back to reference Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011;65:624–35.CrossRefPubMed Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011;65:624–35.CrossRefPubMed
4.
go back to reference Mateus C, Charles C, Robert C. Toxicités cutanées des traitements anticancéreux. In: Scotte F, Krakowski I, editors. Soins de Support en Cancérologie. Paris: Springer; 2016 (in press). Mateus C, Charles C, Robert C. Toxicités cutanées des traitements anticancéreux. In: Scotte F, Krakowski I, editors. Soins de Support en Cancérologie. Paris: Springer; 2016 (in press).
5.
go back to reference Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Oncotarget. 2013;8:173–81. Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Oncotarget. 2013;8:173–81.
6.
go back to reference Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78:8–15.CrossRefPubMed Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78:8–15.CrossRefPubMed
7.
go back to reference Stepanski EJ, Reyes C, Walker MS, et al. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 2013;42:32–6.CrossRefPubMed Stepanski EJ, Reyes C, Walker MS, et al. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 2013;42:32–6.CrossRefPubMed
8.
go back to reference Romito F, Giuliani F, Cormio C, et al. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer. 2010;18:329–34.CrossRefPubMed Romito F, Giuliani F, Cormio C, et al. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer. 2010;18:329–34.CrossRefPubMed
9.
go back to reference Butts M, Jatoi A. Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention? J Support Oncol. 2010;8:162–3.PubMed Butts M, Jatoi A. Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention? J Support Oncol. 2010;8:162–3.PubMed
10.
go back to reference Charles C, Sultan S, Bungener C, et al. Impact des toxicités cutanées associées aux thérapies ciblées sur la qualité de vie—Résultats d’une étude pilote longitudinale. Bull Cancer. 2013;100:213–22.PubMed Charles C, Sultan S, Bungener C, et al. Impact des toxicités cutanées associées aux thérapies ciblées sur la qualité de vie—Résultats d’une étude pilote longitudinale. Bull Cancer. 2013;100:213–22.PubMed
11.
go back to reference Ra HS, Shin SJ, Kim JH, et al. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol. 2013;27:53–9.CrossRef Ra HS, Shin SJ, Kim JH, et al. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol. 2013;27:53–9.CrossRef
12.
go back to reference Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand foot syndrome. Oncologist. 2011;16:1469–78.PubMedCentralCrossRefPubMed Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand foot syndrome. Oncologist. 2011;16:1469–78.PubMedCentralCrossRefPubMed
13.
go back to reference Andreis F, Rizzi A, Mosconi P, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010;8:40.PubMedCentralCrossRefPubMed Andreis F, Rizzi A, Mosconi P, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010;8:40.PubMedCentralCrossRefPubMed
14.
go back to reference Basra MKA, Finlay AY. The family impact of skin diseases: the greater patient concept. Br J Dermatol. 2007;156:929–37.CrossRefPubMed Basra MKA, Finlay AY. The family impact of skin diseases: the greater patient concept. Br J Dermatol. 2007;156:929–37.CrossRefPubMed
15.
go back to reference Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21:54–9.CrossRefPubMed Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21:54–9.CrossRefPubMed
16.
go back to reference Moreira H, Canavarro MC. A longitudinal study about the body image and psychosocial adjustment of breast cancer patients during the course of the disease. Eur J Oncol Nurs. 2010;14:263–70.CrossRefPubMed Moreira H, Canavarro MC. A longitudinal study about the body image and psychosocial adjustment of breast cancer patients during the course of the disease. Eur J Oncol Nurs. 2010;14:263–70.CrossRefPubMed
17.
go back to reference Pruzinsky T. Enhancing quality of life in medical populations: a vision for body image assessment and rehabilitation as standards of care. Body Image. 2004;1:71–81.CrossRefPubMed Pruzinsky T. Enhancing quality of life in medical populations: a vision for body image assessment and rehabilitation as standards of care. Body Image. 2004;1:71–81.CrossRefPubMed
19.
go back to reference Bruchon-Schweitzer M. Dimensionality of the body image: the Body Image Questionnaire. Percept Mot Skills. 1987;65:887–92.CrossRef Bruchon-Schweitzer M. Dimensionality of the body image: the Body Image Questionnaire. Percept Mot Skills. 1987;65:887–92.CrossRef
20.
go back to reference Koleck M, Bruchon-Schweitzer M, Cousson-Gélie F, et al. The body-image questionnaire: an extension. Percept Mot Skills. 2002;94:189–96.CrossRefPubMed Koleck M, Bruchon-Schweitzer M, Cousson-Gélie F, et al. The body-image questionnaire: an extension. Percept Mot Skills. 2002;94:189–96.CrossRefPubMed
21.
go back to reference Charles C, Dauchy S. Étudier l’image du corps en oncologie: un point sur la méthodologie de recherche. Bull Cancer. 2011;98:1209–20.PubMed Charles C, Dauchy S. Étudier l’image du corps en oncologie: un point sur la méthodologie de recherche. Bull Cancer. 2011;98:1209–20.PubMed
22.
go back to reference Dany L, Apostolidis T, Cannone P, et al. Image corporelle et cancer: une analyse psychosociale. Psychooncologie. 2009;3:101–17. Dany L, Apostolidis T, Cannone P, et al. Image corporelle et cancer: une analyse psychosociale. Psychooncologie. 2009;3:101–17.
23.
go back to reference Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996.
24.
go back to reference American Psychiatric Association (APA). DSM-IV-TR manuel diagnostique et statistique des troubles mentaux: texte révisé. Paris: Masson; 2000. American Psychiatric Association (APA). DSM-IV-TR manuel diagnostique et statistique des troubles mentaux: texte révisé. Paris: Masson; 2000.
25.
go back to reference Lacouture ME, Basti S, Patel J, et al. The SERIES Clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol. 2006;4:236–8.PubMed Lacouture ME, Basti S, Patel J, et al. The SERIES Clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol. 2006;4:236–8.PubMed
26.
go back to reference Wagner LI, Berg SR, Gandhi M, et al. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer. 2003;27:419–29. Wagner LI, Berg SR, Gandhi M, et al. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer. 2003;27:419–29.
27.
go back to reference Charles C. Psychosocial repercussions of dermatologic symptoms induced by targeted therapies. Doctoral thesis. Paris: Paris Descartes University; 2014. Charles C. Psychosocial repercussions of dermatologic symptoms induced by targeted therapies. Doctoral thesis. Paris: Paris Descartes University; 2014.
Metadata
Title
Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study
Authors
Cécile Charles
Darius Razavi
Catherine Bungener
Christine Mateus
Emilie Lanoy
Michèle Verschoore
Sarah Dauchy
Caroline Robert
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 3/2016
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0373-8

Other articles of this Issue 3/2016

Clinical Drug Investigation 3/2016 Go to the issue